Graft Versus Host Disease

What is Graft Versus Host Disease (GVHD)?

Graft versus host disease (GVHD) is a complication that can develop after a person has had a bone marrow or stem cell transplant. In the disease, the host body comes under attack from the donated cells.

Types of Graft Versus Host Disease (GVHD)

Symptoms and Diagnosis of Graft Versus Host Disease (GVHD)

Treatment of Graft Versus Host Disease (GVHD)

Causes and Risk Factors of Graft Versus Host Disease (GVHD)

Preventing Graft Versus Host Disease (GVHD)

Research info Graft Versus Host Disease (GVHD)

Graft Versus Host Disease Research

Latest Graft Versus Host Disease News and Research

New stem cell technology gives new hope for high-risk leukemia patients

Few people get a second chance at life. And fewer still are forced to take it before their 25th birthday. Tyler Rabey is one of those people. He was diagnosed with an aggressive form of leukemia at the prime of his life; a cancer that defied all standard treatments.

8 Nov 2019

New stem cell transplant lowers complications for patients with acute blood cancers

The discovery of the UM171 molecule, by Dr. Guy Sauvageau and Anne Marinier, made headlines in 2014 following an article in Science. Hailed by some as a revolution, even a miracle, in the field of blood stem cell transplantation, the UM171 molecule is delivering on its promise.

5 Nov 2019

NCCN publishes new clinical practice guidelines for hematopoietic cell transplantation

Today, the National Comprehensive Cancer Network published new NCCN Clinical Practice Guidelines in Oncology for Hematopoietic Cell Transplantation, also known as stem cell transplant or historically as bone marrow transplant.

30 Oct 2019

Single-cell encapsulation technology can protect transplanted MSCs from immune attack

Bone marrow transplants of hematopoietic stem cells have become standard treatment for a host of conditions including cancers of the blood and lymphatic systems, sickle cell anemia, inherited metabolic disorders, and radiation damage.

16 Jul 2019

Thioredoxin antioxidant could soon be used to improve cancer treatment

Researchers from Medical University of South Carolina (MUSC) have discovered the use of thioredoxin – a naturally occurring antioxidant to modulate T cells of the immune system. This may be a big step towards improving currently used immune therapies such as adoptive T-cell therapy (ACT) and hematopoietic stem cell transplantation (HSCT).

8 Jul 2019

Virus employs powerful strategy to inhibit natural killer cell function

The virus responsible for chickenpox and shingles employs a powerful strategy of immune evasion, inhibiting the ability of natural killer cells to destroy infected cells and produce molecules that help control viral infection, according to a study published June 13 in the open-access journal PLOS Pathogens by Allison Abendroth of the Discipline of Infectious Diseases and Immunology in the Charles Perkins Centre at the University of Sydney, and colleagues.

From PLOS ONE 14 Jun 2019

Benefit of allogeneic stem cell transplantation in non-Hodgkin lymphoma remains unclear

The German Institute for Quality and Efficiency in Health Care has investigated whether patients suffering from non-Hodgkin lymphoma have (better) chances of recovery when stem cells from another person are transplanted.

24 May 2019

Early clinical trial of new treatment for severe dry eye disease shows promising results

Participants in a phase I/II clinical trial of a new enzyme-based treatment for severe dry eye disease experienced reduced signs of disease and discomfort, according to a paper in Translational Vision Science and Technology.

7 May 2019

Study compares use of breast milk to formula in children who underwent bone marrow transplant

A new pilot study compared the use of human breast milk to formula in children less than 5 years of age who underwent bone marrow transplant (BMT), measuring the levels of inflammatory and pro-inflammatory biomarkers in the stool and blood to assess inflammatory injury to the intestinal microbiome.

5 Apr 2019

FDA approves new oral drug to treat relapsing forms of multiple sclerosis

The U.S. Food and Drug Administration today approved Mavenclad (cladribine) tablets to treat relapsing forms of multiple sclerosis (MS) in adults, to include relapsing-remitting disease and active secondary progressive disease.

29 Mar 2019

Deadly inherited blood disorders cured with bone marrow transplant

Doubling the low amount of total body radiation delivered to patients undergoing bone marrow transplants with donor cells that are only "half-matched" increased the rate of engraftment from only about 50 percent to nearly 100 percent, according to a new study by Johns Hopkins researchers.

15 Mar 2019

Using TGS technology to make the perfect match even better for stem cell transplant recipients

At Anthony Nolan we save the lives of people with blood cancers and blood disorders that need a stem cell transplant.

4 Mar 2019

New forms of older anti-cancer agent appear to enhance immune response to fight melanoma

Researchers at the Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins and the Johns Hopkins University School of Medicine report two new forms of an older anti-cancer agent they developed appear to enhance the immune system's ability to fight melanoma in mice.

20 Feb 2019

Researchers explain why T cells lose their protective ability in inflamed tissues

Regulatory T cells make sure that immune responses are not too strong and that inflammation is inhibited. This makes them highly interesting for therapies against inflammatory autoimmune diseases such as multiple sclerosis.

20 Feb 2019

New bioengineered device enhances the production of T-cells

Bone marrow transplants, also known as hematopoietic stem cell transplants, are life-saving treatments for aggressive diseases, such as leukemia and multiple myeloma, and infections such as HIV. The procedure entails infusion of blood stem cells from a matched donor into the patient to 'reset' the blood and immune system.

12 Feb 2019

Research could provide a new way to treat organ scarring in future

The increased deposition of connective tissue is a problem in chronic diseases of many organs such as the lungs, liver, kidneys, gut, and the skin.

6 Feb 2019

Researchers succeed in converting human skin cells into blood stem cells

Researchers have succeeded in converting human skin cells into blood stem cells in an international collaboration project.

5 Dec 2018

Scientists harness power of natural killer cells to treat children with neuroblastoma

Researchers have made rapid advances in understanding how to manipulate the immune system safely to destroy cancer cells. Adoptive transfer of haploidentical natural killer (NK) cells has shown promise as a treatment option to target and kill cancer cells in a less toxic way than conventional therapies.

14 Nov 2018

Auto-FMT found to be safe, effective way to replenish beneficial gut bacteria in cancer patients

Researchers at Memorial Sloan Kettering Cancer Center have shown that autologous fecal microbiota transplantation (auto-FMT) is a safe and effective way to help replenish beneficial gut bacteria in cancer patients who require intense antibiotics during allogenic hematopoietic stem cell transplantation.

27 Sep 2018

Mesoblast’s MPC therapy for children featured at symposium for congenital heart disease

Mesoblast Limited today announced that Mesoblast's proprietary allogeneic mesenchymal precursor cell heart failure product candidate MPC-150-IM for use in children with hypoplastic left heart syndrome was featured at the First Cardiac Regenerative Symposium for Congenital Heart Disease in Baltimore, Maryland on the weekend.

26 Sep 2018